Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer

Figure 1:

Figure 2:

mPD-L1 expression ratio in some clinical trials on NSCLC_

Clinical trials	Positive mPD-L1 expression ratio	PD-L1 antibody type
CheckMate 057[18]	455/582 (78%)	28-8
CheckMate 017[19]	225/272 (83%)	28-8
CheckMate 012[20]	32/46 (70%)	28-8
CheckMate 227[21]	1189/1739 (68%)	28-8
Keynote 189[22]	63%	22C3
Keynote 001[23]	60,8%	22C3
Keynote 010[24]	1475/2222 (66%)	22C3
Keynote 021[25]	56,8%	22C3
Keynote 042[26]	1978/3019 (66%)	22C3
Keynote 024[27]	500/1653 (30,2%)	22C3
POPLAR[28]	109/287 (37,9%)	SP142
JAVELIN Lung 100[29]	88/156 (56,4%)	73-10
JAVELIN Lung 200[30]	527/792 (66%)	73-10

Values of sPD-L1 concentration according to clinical and paraclinical characteristics_

Feature	Subgroup	Median (IQR)	p**
Gender	Male (n = 59)	1.09 (0.5 – 2.56)	0.67
	Female (n = 21)	0.93 (0.6 – 1.49)
Smoking	Yes (n = 38)	1.08 (0.56 – 2.43	0.965
	No (n = 42)	1.03 (0.59 – 2.28)
Staging	IIIB (n = 16)	1.06 (0.68 – 2.16)	0.764
	IV (n = 64)	1.08 (0.52 – 2.36)
Age	≤ 65 (n = 40)	1.04 (0.55 – 2.49)	0.577
	> 65 (n = 40)	1.1 (0.67 – 2.27)
Tumor size	< 30 mm (n = 27)	1.49 (0.65 – 2.29)	0.981
	≥ 30 mm (n = 53)	1.07 (0.56 – 2.28)
Phenotype	ADC (n = 58)	0.96 (0.59 – 2.25)	0.763
	SCC (n = 16)	1.17 (0.46 – 2.24)
	ASC (n = 6)	2.0 (0.57 – 3.59)
EGFR mutation	Positive (n = 24)	1.125 (0.69 – 2.2125)	0.187
	Negative (n = 56)	2.56 (0.865 – 4.80)

Logistic regression model between increased sPD-L1 and mPD-L1 and clinical and paraclinical characteristics of NSCLC_

sPDL1 expression low – high	OR	SE	z	p	95% CI
Age	1.06	0.0317	1.85	0.065	0.996	1.121
Gender	0.34	0.2732	−1.34	0.179	0.072	1.635
BMI	0.86	0.1049	−1.27	0.204	0.673	1.088
Disease duration	1.003	0.0068	0.52	0.604	0.990	1.017
Clubbing	9.49	14.413	1.48	0.139	0.483	186.36
Bronchial Obstruction	0.06	0.0753	−2.19	0.029	0.004	0.7417
Tumor size	1.01	0.0152	0.77	0.442	0.982	1.042
Metastases	0.21	0.2167	−1.51	0.131	0.027	1.595
ADC	0.79	0.5333	−0.35	0.726	0.209	2.968
_cons	1.56	5.2885	0.13	0.896	0.002	1202.81
p = 0.031; R2 = 0.20

Characteristics of study subjects_

Feature	NSCLC (n1 = 80)	Control (n2 = 30)	p
General Characteristics
Age (X ± SD) (years)	65.58 ± 12.15	61.23 ± 15.84	0.096*
Male	59 (73.75%)	14 (46.67%)	0.007a
Female	21 (26.25%)	16 (53.33%)
Smoking	38 (47.5%)	8 (26.67%)	< 0.049a
BMI	20,85 ± 2,41	21,1 ± 2,06	0.624*
Clinical Features:
Fatigue	36 (45.0%)	0
Weight loss	32 (40.0%)	0
Fever	11 (13.75%)	0
Clubbing	7 (8.75%)	0
Peripheral Lymphadenopathy	15 (18.75%)	0
Cough	66 (82.5%)	0
Sputum	22 (27.5%)	0
Hemoptysis	9 (11.25%)	0
Chest pain	52 (65.0%)	0
Dyspnea	29 (36.25%)	0
Bronchial Obstruction	6 (7.5%)	NA
Consolidation syndrome	11 (13.92%)	NA
Pleural effusion	36 (45.0%)	NA
Mediastinal Syndrome	4 (5.0%)	NA
CT Chest Imaging Characteristics:
Nodules	27 (23.75%)	NA
Mass	53 (66.25%)	NA
Largest Tumor Size (X±SD) (mm)	47.73 ± 21.46	NA
Pleural effusion	38 (47.5%)	NA
Mediastinal lymph nodes	21 (26.25%)	NA
Atelectasis	15 (18.75%)	NA
Staging		NA
IIIB	16 (20.0%)	NA
IV	64 (80.0%)	NA
Pathology and Gene mutations:
ADC	58 (72.5%)	NA
SCC	16 (20.0%)	NA
ASC	6 (7.5%)	NA
EGFR mutation	24 (30.0%)	NA
sPD-L1 in PBMC:
Median (Min – Max)	1.08 (0.01 – 5.56)	0.42 (0.01 – 1.66)	< 0.001**
mPD-L1 molecular expression:
Negative	31 (38.75%)	NA
Positive	49 (61.25%)	NA
Expression level
- Low (1 – 49%)	26 (32.5%)	NA
- High (≥ 50%)	23 (28.75)	NA
Median (min – max)	10 (0 – 50)	NA
X ± SD (%)	27.82 ± 33.61	NA

Relationship between mPD-L1 and sPD-L1 expression_

mPD-L1 expression		sPD-L1 Median (IQR)	p**
Not expressed (n = 31)		0.93 (0.48 – 2.06)	0.304
Expressed (n = 49)		1.09 (0.64 – 2.56)
Expression level	- Low (n = 26)	1.21 (0.65 – 2.7)	0.726
	- High (n = 23)	1.04 (0.49 – 2.56)